Home > Boards > US Listed > Biotechs > Exact Sciences (EXAS)

Exact Sciences (EXAS) Stock Has 40% Upside From

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
realfast95 Member Profile
Member Level 
Followed By 50
Posts 14,827
Boards Moderated 1
Alias Born 11/29/06
160x600 placeholder
Annual Report of Employee Stock Plans (11-k) Edgar (US Regulatory) - 6/30/2020 9:19:00 AM
Oncotype DX Genomic Prostate Score® Result Shows for the First Time the Value of the Test to Guide Treatment Plans for Unfav... PR Newswire (US) - 6/16/2020 8:00:00 AM
Prospectus Filed Pursuant to Rule 424(b)(7) (424b7) Edgar (US Regulatory) - 6/2/2020 6:08:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 6:01:05 AM
Automatic Shelf Registration Statement of Securities of Well-known Seasoned Issuers (s-3asr) Edgar (US Regulatory) - 6/1/2020 4:11:07 PM
Exact Sciences Showcases Continued Progress in Cancer Diagnostics at ASCO 2020 PR Newswire (US) - 5/29/2020 8:00:00 AM
Exact Sciences to participate in June investor conferences PR Newswire (US) - 5/26/2020 6:00:00 AM
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results PR Newswire (US) - 5/14/2020 6:00:00 AM
New Oncotype DX® Real-world Evidence Shows for the First Time the Practice-changing Impact of TAILORx Results PR Newswire (US) - 5/14/2020 6:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/6/2020 4:11:26 PM
Exact Sciences Announces First Quarter 2020 Results PR Newswire (US) - 5/6/2020 4:05:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2020 4:04:20 PM
New Model Shared at Digestive Disease Week (DDW) Demonstrates the Value of Cologuard® When Using Real-World Adherence Rates ... PR Newswire (US) - 5/5/2020 10:30:00 AM
Exact Sciences to participate in May investor conference PR Newswire (US) - 5/4/2020 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/29/2020 4:11:47 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/29/2020 4:10:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/24/2020 4:51:53 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/24/2020 4:48:25 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/24/2020 8:13:15 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2020 4:19:39 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/22/2020 4:15:20 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/21/2020 4:33:30 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/17/2020 4:30:30 PM
Exact Sciences schedules first-quarter 2020 earnings call PR Newswire (US) - 4/8/2020 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/6/2020 4:41:56 PM
realfast95 Member Level  Wednesday, 01/15/20 06:40:13 AM
Re: None
Post # of 609 
Exact Sciences (EXAS) Stock Has 40% Upside From Here, Says Analyst
Maya Sasson January 14, 2020

Exact Sciences’ (EXAS) preliminary quarterly results blew expectations out of the water.

Yesterday, the molecular diagnostics company released preliminary results for its fourth quarter that exceeded analysts’ estimates. Total revenue for the quarter is expected to land between $294 million and $296 million, reflecting a top-line beat of about $4 million to $6 million.

The better-than-expected outcome was primarily driven by its acquisition of Genomic Health, which was finalized back in November and gave it access to Oncotype DX gene expression tests that have been used in treatment decisions for over 1 million cancer patients globally. During the quarter, Oncotype DX test volume growth of 14%, or total test volume of 41,000, helped Genomic Health generate revenue of between $118 and $119 million, up 13% year-over-year.

On top of this, Cologuard, its FDA approved noninvasive, at-home colon cancer screening test, will most likely see revenue come in within the range of $229 million to $230 million. While this falls in line with the consensus estimate, BTIG analyst Amanda Murphy reminds investors that the difference between consensus and guidance is the highest it has been this year. She points out that “consensus for Cologuard revenue was at the high-end of management’s guidance range for the quarter.” If achieved, the figure would also represent a year-over-year increase of 61%.

Based on the expected Cologuard revenue, it isn’t surprising to the analyst, then, that volumes for the screening test are also expected to match the estimate. The results indicate Cologuard test volume of 477,000 could be in store. This, however, would not only come in above management’s guidance of between 465,000 to 475,000, but also reflect impressive growth of 63%.

While management isn’t offering any 2020 guidance before its earnings call in February, Murphy notes that the results reaffirm her already established bullish thesis. “Since Cologuard was approved in 2014, Exact has secured broad reimbursement coverage, developed a large and experienced sales force, increased its lab capacity to seven million tests per year, and made significant investments in IT infrastructure. We believe Cologuard is currently at an inflection point and expect the company to hit its long-term goal of 40% market penetration by the end of 2030,” she explained. The four-star analyst added, “While not explicitly included in our current valuation model, we are also optimistic around the potential for Exact’s liquid biopsy test for liver cancer.”

Bearing this in mind, Murphy maintained both a Buy rating as well as a $127 price target. This conveys her confidence in Exact’s ability to climb 40% higher in the next twelve months. (To watch Murphy’s track record, click here)

As for the rest of the Street? It turns out that other analysts wholeheartedly agree with the BTIG analyst. Out of 9 total analysts that have published a recommendation over the last three months, 100% see the stock as a Buy. This makes the consensus rating a unanimous Strong Buy. Not to mention the $123.56 average price target puts the upside potential just below Murphy’s forecast at 37%.

https://blog.tipranks.com/exact-sciences-exas-stock-has-40-upside-from-here-says-analyst/

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist